Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Stock Information for Corbus Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.